315 related articles for article (PubMed ID: 32975679)
1. Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial.
Taheri H; Malek M; Ismail-Beigi F; Zamani F; Sohrabi M; Reza Babaei M; Khamseh ME
Adv Ther; 2020 Nov; 37(11):4697-4708. PubMed ID: 32975679
[TBL] [Abstract][Full Text] [Related]
2. Effect of Empagliflozin and Pioglitazone on left ventricular function in patients with type two diabetes and nonalcoholic fatty liver disease without established cardiovascular disease: a randomized single-blind clinical trial.
Attaran F; Emami S; Sohrabi M; Malek M; Ajdarkosh H; Khoonsari M; Ismail-Beigi F; Khamseh ME
BMC Gastroenterol; 2023 Sep; 23(1):327. PubMed ID: 37742004
[TBL] [Abstract][Full Text] [Related]
3. Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: Study protocol for a randomized clinical trial.
Lin YH; Zhang ZJ; Zhong JQ; Wang ZY; Peng YT; Lin YM; Zhang HP; Tian JQ
PLoS One; 2024; 19(5):e0302155. PubMed ID: 38701096
[TBL] [Abstract][Full Text] [Related]
4. Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASH.
Perakakis N; Chrysafi P; Feigh M; Veidal SS; Mantzoros CS
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34199317
[TBL] [Abstract][Full Text] [Related]
5. Comparison between the effect of Empagliflozin and Pioglitazone added to metformin in patients with type 2 diabetes and nonalcoholic fatty liver disease.
Hooshmand Gharabagh L; Shargh A; Mohammad Hosseini Azar MR; Esmaeili A
Clin Res Hepatol Gastroenterol; 2024 Mar; 48(3):102279. PubMed ID: 38159676
[TBL] [Abstract][Full Text] [Related]
6. Evolution of liver fibrosis in diabetic patients with NAFLD in a follow-up study: Hepatoprotective effects of sodium-glucose co-transporter-2 inhibitors.
Lombardi R; Mantovani A; Cespiati A; Francione P; Maffi G; Del Zanna E; Maffeis C; Colecchia A; Passigato N; Ferrarese A; Cusumanu CD; Villani R; Orsi E; Grancini V; Airaghi L; Bignamini D; Serviddio G; Targher G; Dongiovanni P; Fargion S; Fracanzani AL
Dig Liver Dis; 2024 Apr; 56(4):551-558. PubMed ID: 37845152
[TBL] [Abstract][Full Text] [Related]
7. Hepatoprotective effects of gemigliptin and empagliflozin in a murine model of diet-induced non-alcoholic fatty liver disease.
Lee N; Heo YJ; Choi SE; Jeon JY; Han SJ; Kim DJ; Kang Y; Lee KW; Kim HJ
Biochem Biophys Res Commun; 2022 Jan; 588():154-160. PubMed ID: 34971904
[TBL] [Abstract][Full Text] [Related]
8. The effects of grape seed extract supplementation on cardiovascular risk factors, liver enzymes and hepatic steatosis in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.
Ghanbari P; Raiesi D; Alboebadi R; Zarejavid A; Dianati M; Razmi H; Bazyar H
BMC Complement Med Ther; 2024 May; 24(1):192. PubMed ID: 38755622
[TBL] [Abstract][Full Text] [Related]
9. Serum thrombospondin-2 level changes with liver stiffness improvement in patients with type 2 diabetes.
Mak JHC; Lui DT; Fong CH; Cheung CY; Wong Y; Lee AC; Hoo RL; Xu A; Tan KC; Lam KS; Lee CH
Clin Endocrinol (Oxf); 2024 Mar; 100(3):230-237. PubMed ID: 38127469
[TBL] [Abstract][Full Text] [Related]
10. Antianginal effects of empagliflozin in patients with type 2 diabetes and refractory angina; a randomized, double-blind placebo-controlled trial (EMPT-ANGINA Trial).
Mansouri MH; Mansouri P; Sadeghi M; Hashemi SM; Khosravi A; Behjati M; Shahabi J; Mansouri A; Zavar R; Amirpour A; Sanei H; Sarrafzadegan N
Clin Cardiol; 2024 Jan; 47(1):e24158. PubMed ID: 37721420
[TBL] [Abstract][Full Text] [Related]
11. Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Evaluation of Hepatic Fibrosis and Steatosis Using Fibroscan.
Tuong TTK; Tran DK; Phu PQT; Hong TND; Dinh TC; Chu DT
Diagnostics (Basel); 2020 Mar; 10(3):. PubMed ID: 32183383
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of vitamin D supplementation on adult patients with non-alcoholic fatty liver disease: a single-center experience.
Gad AI; Elmedames MR; Abdelhai AR; Marei AM; Abdel-Ghani HA
Gastroenterol Hepatol Bed Bench; 2021; 14(1):44-52. PubMed ID: 33868609
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic outcome of dapagliflozin in patients with type 2 diabetes and non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.
Hu C; Qu T; Li L; Huang Y; Liu H; Rao C
Afr Health Sci; 2023 Jun; 23(2):416-421. PubMed ID: 38223613
[TBL] [Abstract][Full Text] [Related]
14. Dietary approaches to stop hypertension (DASH) diet improves hepatic fibrosis, steatosis and liver enzymes in patients with non-alcoholic fatty liver disease: a randomized controlled trial.
Sangouni AA; Nadjarzadeh A; Rohani FS; Sharuni F; Zare Z; Rahimpour S; Hojjat H; Hosseinzadeh M
Eur J Nutr; 2024 Feb; 63(1):95-105. PubMed ID: 37855891
[TBL] [Abstract][Full Text] [Related]
15. Effects of empagliflozin on liver fat in patients with metabolic dysfunction-associated steatotic liver disease without diabetes mellitus: A randomized, double-blind, placebo-controlled trial.
Cheung KS; Ng HY; Hui RWH; Lam LK; Mak LY; Ho YC; Tan JT; Chan EW; Seto WK; Yuen MF; Leung WK
Hepatology; 2024 Mar; ():. PubMed ID: 38536017
[TBL] [Abstract][Full Text] [Related]
16. Effects of Empagliflozin Treatment on Glycerol-Derived Hepatic Gluconeogenesis in Adults with Obesity: A Randomized Clinical Trial.
Neeland IJ; de Albuquerque Rocha N; Hughes C; Ayers CR; Malloy CR; Jin ES
Obesity (Silver Spring); 2020 Jul; 28(7):1254-1262. PubMed ID: 32568464
[TBL] [Abstract][Full Text] [Related]
17. Effect of dapagliflozin on liver and pancreatic fat in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Shi M; Zhang H; Wang W; Zhang X; Liu J; Wang Q; Wang Y; Zhang C; Guo X; Qiao Q; Cui C; Xu J; Wang J
J Diabetes Complications; 2023 Oct; 37(10):108610. PubMed ID: 37722211
[TBL] [Abstract][Full Text] [Related]
18. The Effects of Ginger (
Ghoreishi PS; Shams M; Nimrouzi M; Zarshenas MM; Lankarani KB; Fallahzadeh Abarghooei E; Talebzadeh M; Hashempur MH
J Diet Suppl; 2024; 21(3):294-312. PubMed ID: 37817641
[TBL] [Abstract][Full Text] [Related]
19. Misoprostol for non-alcoholic steatohepatitis: a randomised control trial.
Siyal M; Abbas Z; Qadeer MA; Saeed A; Ali U; Khatoon A
BMJ Open Gastroenterol; 2024 Jun; 11(1):. PubMed ID: 38844374
[TBL] [Abstract][Full Text] [Related]
20. Advanced liver fibrosis but not steatosis is independently associated with albuminuria in Chinese patients with type 2 diabetes.
Yeung MW; Wong GL; Choi KC; Luk AO; Kwok R; Shu SS; Chan AW; Lau ESH; Ma RCW; Chan HL; Chan JC; Wong VW; Kong AP
J Hepatol; 2017 Oct; ():. PubMed ID: 28989092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
